• Jack Cuzick, Mangesh A Thorat, Gerald Andriole, Otis W Brawley, Powel H Brown, Zoran Culig, Rosalind A Eeles, Leslie G Ford, Freddie C Hamdy, Lars Holmberg, Dragan Ilic, Timothy J Key, Carlo La Vecchia, Hans Lilja, Michael Marberger, Frank L Meyskens, Lori M Minasian, Chris Parker, Howard L Parnes, Sven Perner, Harry Rittenhouse, Jack Schalken, Hans-Peter Schmid, Bernd J Schmitz-Dräger, Fritz H Schröder, Arnulf Stenzl, Bertrand Tombal, Timothy J Wilt, and Alicja Wolk.
• Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. Electronic address: j.cuzick@qmul.ac.uk.
• Lancet Oncol. 2014 Oct 1; 15 (11): e484e492e484-92.

AbstractProstate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.Copyright © 2014 Elsevier Ltd. All rights reserved.

32 keywords...

hide…